01 December 2022
EMA/CHMP/878170/2022 Rev.2
Human Medicines Division

Committee for medicinal products for human use (CHMP)

PROM[1] agenda for the meeting on 5 December 2022

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

5 December 2022, 09:00–16:00, virtual meeting/room 08-A

Disclaimers

Some of the information contained in this document is considered commercially confidential or sensitive and therefore not disclosed.

Of note, agendas and minutes are working documents primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

[1] The CHMP PReparatory and Organisational Matters (PROM) is a meeting to discuss CHMP organisational matters and other topics in preparation for the CHMP Plenary meeting. It is a virtual meeting, which usually takes place on Monday before the CHMP Plenary meeting. CHMP members, working party chairs and national experts together with EMA staff are participating in this forum. Depending on the nature of the issue and availability of documents and experts some PROM topics can be discussed at the CHMP Plenary.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged.

Table of contents

1. Agenda and Minutes 4
1.1. Welcome and declarations of interest of members, alternates and experts 4
1.2. Adoption of agenda 4
1.3. Adoption of the minutes 4
2. Quality Domain 4
2.1. Biologics Working Party (BWP) 4
2.2. Quality Working Party (QWP) 4
2.3. Biosimilar Medicinal Product Working Party (BMWP) 5
2.4. Quality Innovation Group (QIG) 6
2.5. Formulation Expert Group (FEG) 6
3. Non-Clinical Domain 6
3.1. Non-Clinical Working Party (NcWP) 6
3.2. Joint 3Rs Replacement, Reduction and Refinement Working Party (3Rs) 7
4. Methodology Domain 8
4.1. Methodology Working Party (MWP) 8
4.2. Biostatistics Operational Expert Group (BOEG) 8
4.3. Modelling and Simulation Operational Expert Group (MSOEG) 9
4.4. Real World Data Operational Expert Group (RWDOEG) 9
4.5. Pharmacokinetics Working Party (PKWP) 9
5. Clinical Domain 9
5.1. Central Nervous System Working Party (CNSWP) 9
5.2. Cardiovascular Working Party (CVSWP) 10
5.3. Oncology Working Party (ONCWP) 10
5.4. Rheumatology and Immunology Working Party (RIWP) 11
5.5. Infectious Disease Working Party (IDWP) 11
5.6. Vaccines Working Party (VWP) 12
5.7. Haematology Working Party (HaemWP) 12
5.8. Scientific Advisory Groups (SAGs) and Ad-hoc Expert Groups (AHEG) 12
6. Patients, Healthcare Professionals and Consumers 12
6.1. Patients and Consumers Working Party (PCWP) Healthcare Professionals Working Party (HCPWP) 12
7. Harmonisation and consistency groups 12
7.1. International Council on Harmonisation (ICH) 12
7.2. Guideline Consistency Group (GCG) 13

7.3. Summary of product characteristics Advisory Group 13
8. Joint groups and collaboration with other Scientific committees 13
8.1. Joint CHMP/CVMP/CMDh/CMDv Working Group on Active Substance Master File Procedures (ASMF WG) 13
8.2. Collaboration with other Scientific committees 13
9. Regulatory/Organisational matters 14
9.1. Regulatory Issues/new legislation 14
9.2. CHMP organisation/templates 14
10. Product development support 14
10.1. Scientific Advice Working Party (SAWP) 14
10.2. Innovation Task Force 14
11. Product related topics 15
11.1. Preview CHMP Plenary 15
11.2. COVID-19 ongoing and upcoming procedures 15
12. Any Other Business 15
12.1. Rapporteurships 15
12.2. Diabetes Drafting Group - Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus - (CPMP/EWP/1080/00) 15
12.3. Regulatory & Scientific conference on RNA based medicines 15
12.4. Update on IRIS for core regulatory procedures 16
12.5. EMA labelling review process improvement 16
12.6. Q&A "Is the monitoring of bioequivalence clinical trials mandatory?" 16

1. Agenda and Minutes

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PROM meeting to be held on 5 December 2022. As the PROM is a preparatory meeting for the CHMP plenary session, restrictions and declarations of interests applicable to the items in the draft agenda of the upcoming CHMP plenary session are also considered. See December 2022 PROM minutes.

1.2. Adoption of agenda

CHMP PROM agenda for 5 December 2022 meeting

1.3. Adoption of the minutes

CHMP PROM Minutes of 5 December 2022 meeting will be adopted at the December 2022 CHMP plenary.

2. Quality Domain

2.1. Biologics Working Party (BWP)

Chairs: Sol Ruiz, Sean Barry

2.1.1. Call for nomination for the BWP Chair

BWP Chair Sol Ruiz's last term will expire in February 2023. A call of nomination for a new BWP Chair is being launched. Nominations should be sent to the Agency. Candidates are kindly asked to submit a brief CV in support of their candidature together with a cover letter highlighting their expertise.

The election will take place at the February 2023 CHMP plenary meeting.

Action: For information

2.1.2. Agenda and minutes

- Agenda for the BWP meeting to be held by Webex on 5-7 December 2022
- Minutes of the BWP meeting held F2F on 3-5 October 2022

Action: For information

2.2. Quality Working Party (QWP)

Chairs: Blanka Hirschlerova, Marie-Hélène Sabinotto, Laivi Saaremäe

2.2.1. Call for nomination for the QWP Chair

QWP Chair Blanka Hirschlerova's first term will expire in February 2023. A new call of nomination for a QWP chair is being launched. Nominations should be sent to the Agency. Candidates are kindly asked to submit a brief CV in support of their candidature together with a cover letter highlighting their expertise.

The election will take place at the January 2023 CHMP plenary meeting.

Action: For information

2.2.2. Minutes

- Final minutes of QWP meeting held F2F in September 2022
- Final minutes of joint GMDP IWG – QWP meeting held F2F in September 2022

Action: For information

2.2.3. QWP Core Team Agenda

- Final agenda and minutes for QWP-CT meeting held by teleconference on 3 November 2022

Action: For information

2.2.4. QWP workplan

The workplan has been agreed by the QWP and is presented to the CHMP for adoption.

Action: For adoption

2.2.5. CMDh letter regarding mobile tank containers for medicinal gases

Response to the CMDh letter regarding mobile tank containers for medicinal gases agreed by QWP and IWG.

Action: For adoption

2.3. Biosimilar Medicinal Product Working Party (BMWP)

Chairs: Elena Wolff-Holz, Niklas Ekman

2.3.1. Agenda and minutes

- Agenda of the BMWP meeting held by Webex on 23 November 2022

Action: For information

2.3.2. A data driven approach to support tailored clinical programmes for biosimilar monoclonal antibodies

Presentation of research on biosimilars accepted for publication by Clinical Pharmacology and Therapeutics (expected for publication in January 2023).

BMWP: Elena Wolff-Holz, Niklas Ekman

Action: For information

2.4. Quality Innovation Group (QIG)

No topics

2.5. Formulation Expert Group (FEG)

No topics

3. Non-Clinical Domain

3.1. Non-Clinical Working Party (NcWP)

Chairs: Susanne Brendler-Schwaab, Karen van Malderen

3.1.1. Agenda and minutes

- Draft minutes for the NcWP meeting held virtually on 3-4 November 2022
- Draft agenda for the NcWP meeting to be held virtually on 6-7 December 2022

Action: For information

3.1.2. CMDh questions to NcWP on new nitrosamines

CMDh requests that the NcWP determines the acceptable intake for the following nitrosamines based on lifetime daily exposure including information on the points of departure and methodology used.

- 2-Nitroso-octahydrocyclopenta(c)pyrrole
- "Nitroso impurity C" [N-(2,6-dimethylphenyl)-2-(4-nitrosopiperazin-1-yl)acetamide]

Action: For adoption

3.1.3. Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products

Following the CHMP adoption of NcWP positions on new nitrosamines in November, the question 10 of the Q&A document has been updated to include the limits for:

- N-nitroso-fluoxetine
- N-nitrosoparoxetine
- N-nitroso-diphenylamine NDPh
- N-nitroso-mefenamic acid
- N-nitroso-pyrrolidine NPYR
- N-nitroso-diethanolamine NDELA

Action: For adoption

3.1.4. NcWP response to third party on the SWP response to CMDh on genotoxicity and contraception

In February 2020, based on a request from CMDh, the Safety working party (SWP) published advice on the duration of contraception in male and female patients after cessation of treatment with a genotoxic drug in the context both of clinical trial applications as well as marketing authorisation applications (EMA/CHMP/SWP/74077/2020). In July 2022, the CMDh and EMA have received questions from a third-party which NcWP addressed.

NcWP Chair: Susanne Brendler-Schwaab

Action: For adoption

3.1.5. NcWP response to CMDh question on potentially mutagenic impurity chloromethyl isopropyl carbonate (CMIC) in tenofovir disoproxyl-containing medicinal products

At the July 2022 CMDh meeting, the CMDh discussed the potentially mutagenic impurity chloromethyl isopropyl carbonate (CMIC) in tenofovir disoproxyl-containing medicinal products. The CMDh agreed to request an assessment by the Non-clinical Working Party to determine the mutagenic risk of CMIC, based on the existing data.

NcWP member: Louise Bang-Lauritsen

Action: For adoption

3.1.6. New nomination in the Excipients Drafting Group

Nomination of experts for the drafting group for the revision of the Annex to guideline on 'Excipients in the labelling and package leaflet of medicines for human use' (EMA/CHMP/302620/2017).

Action: For information

3.1.7. CMDh request to NcWP/ExcpDG on benzyl alcohol

Request to include a threshold dose above zero for orally applied medicinal products in the Annex to the Guideline on Excipients in the labelling and package leaflet of medicinal products for human use in order to remove unnecessary labelling requirements for medicinal products containing traces of benzyl alcohol only.

NcWP Chair: Susanne Brendler-Schwaab

Action: For adoption

3.2. Joint 3Rs Replacement, Reduction and Refinement Working Party (3Rs)

No topics

4. Methodology Domain

4.1. Methodology Working Party (MWP)

Chairs: Kit Roes, Kristin Karlsson

4.1.1. Agenda and minutes

- Final Agenda & minutes for MWP meetings held by teleconference on 17 November 2022

Action: For information

4.1.2. MWP 3-year workplan

The 3 years workplan including priorities was endorsed by the MWP on 17 November 2022.

Action: For adoption

4.1.3. Call for nominations for Methodology European Specialised Expert Community (ESEC)

Following the re-organisation of the EMA Working Parties and the set-up of the new Methodology Domain and Methodology Working Party (MWP), MWP is launching an open call for Methodology European Specialised Expert Community (ESEC).

Committee members are invited to nominate experts in the area of e.g. statistics, clinical trial methodology, modelling & simulation, physiological based pharmacokinetic (PBPK) modelling and simulation, pharmacokinetics, pharmacogenomics, epidemiology, Real World Evidence, or artificial intelligence that are part of the European Regulatory Network (e.g. assessors working for a NCA, members of the different WPs or members from academia in institutions/universities with relevant expertise for the Methodology ESEC).

Nominations (along with a brief summary their expertise) should be sent to the Agency.

Action: For information

4.1.4. Reflection paper on establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation

Presentation about the scope and content of the reflection paper on single-arm trials from the CHMP work plan which is also part of the 3-year work plan from the MWP. The objective is to have the reflection paper adopted by CHMP in Q1 2023 and published for public consultation.

Presenter: Kit Roes (MWP chair)

Action: For information

4.2. Biostatistics Operational Expert Group (BOEG)

No topics

4.3. Modelling and Simulation Operational Expert Group (MSOEG)

No topics

4.4. Real World Data Operational Expert Group (RWDOEG)

No topics

4.5. Pharmacokinetics Working Party (PKWP)

Chair: Carolien Versantvoort

4.5.1. Product-specific guidelines

Final product-specific guidelines

- Lanreotide acetate, prolonged-release solution for injection in pre-filled syringe 60, 90 and 120 mg product-specific bioequivalence guidance (EMA/559891/2021) and Overview of comments
- Liposomal amphotericin B powder for dispersion for infusion 50 mg product-specific bioequivalence guidance (EMA/596406/2022) and Overview of comments

Both guidelines have been finalised following 3-month public consultation and consideration of the comments received.

Action: For adoption

4.5.2. PKWP Q&A 3.12 on whether viscosity and/or other in vitro comparative data are needed to demonstrate comparable physicochemical characteristics of oily solutions, sufficient to support a biowaiver

CMDh sent a query for PKWP input that was agreed by the CHMP in July 2021 relating to a procedure in which a general issue was raised on Appendix II of the 'Guideline on the investigation of bioequivalence' (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **) relating to oily parenteral solutions. The PKWP response was adopted at the CHMP December 2021 PROM with support for a Q&A on the topic. The resulting Q&A (which CMDh also supported) has now been finalised for publication with QWP input to the wording of the original PKWP response (viscosity as a quality attribute).

Action: For adoption

5. Clinical Domain

5.1. Central Nervous System Working Party (CNSWP)

Chair: Andre Elferink, Vice-Chair: Ewa Balkowiec Iskra

5.1.1. CNSWP 3-year work plan

CNSWP adopted the final work plan during 2 December meeting.

Action: For adoption

5.1.2. CNS WP drafting group membership

CHMP is asked to confirm the appointment of membership of drafting groups for migraine, depression, epilepsy and bipolar disorder guidelines.

Action: For endorsement

5.1.3. Agenda and minutes

- Agenda of the CNS WP meeting held by Teams on 9 September 2022
- Minutes of the CNS WP meeting held by Teams on 9 September 2022
- Agenda of the CNS WP meeting held by Teams on 2 Dec 2022

Action: For information

5.2. Cardiovascular Working Party (CVSWP)

Chairs: Alar Irs, Patrick Vrijlandt

5.2.1. ESEC – Cardiovascular Diseases mandate adoption

Preparations for the ESEC-Cardiovascular Diseases, the CVSWP adopted its mandate.

Action: For adoption

5.2.2. ESEC – Cardiovascular Diseases members' appointment

CHMP is asked to confirm the automatic appointment of members of the CVSWP and SAG CV issues as ESEC members.

Action: For endorsement

5.2.3. Agenda and minutes

- Agenda of the CVSWP face-to-face meeting held on 11 November 2022
- Minutes of the CVS WP face-to-face meeting held on 11 November 2022

Action: For information

5.3. Oncology Working Party (ONCWP)

Chair: Pierre Demolis, Vice-Chair: Olli Tenhunen

5.3.1. Agenda and minutes

- Agenda of the ONCWP meeting held by Webex on 25 November 2022
- Minutes of the ONCWP meeting held by Webex on 19 October 2022

Action: For information

5.3.2. Nomination of Oncology ESEC experts

Nomination by ONCWP of an expert to enter the Oncology European Specialised Expert Community (ESEC).

Action: For endorsement

5.3.3. Oncology ESEC activities

The CHMP to be updated on the Oncology ESEC activities.

Action: For information

5.3.4. ONCWP 3-year workplan

The workplan has been edited to reflect changes in chairs positions. In addition, an annex is included listing an update on the work done in 2022.

Action: For adoption

5.4. Rheumatology and Immunology Working Party (RIWP)

Vice-Chair: Caroline Auriche

5.4.1. RIWP 3-year Workplan

The 3-year workplan was endorsed by the RIWP on 7 November 2022.

Vice-Chair: Caroline Auriche

Action: For adoption

5.4.2. Nomination of a new member to the RIWP

Nomination of a new RIWP members. The call for nomination of a new RIWP member was launched at November PROM with a deadline for nominations by 25 November 2022.

Action: For endorsement

5.4.3. Call for nominations for the RIWP Chair

Candidates are kindly asked to submit a brief CV in support of their candidature together with a cover letter highlighting their expertise. Nominations should be sent to the Agency. Proposed candidates must be already members of the RIWP.

Elections will take place at the January 2023 CHMP Plenary meeting.

Action: For information

5.5. Infectious Disease Working Party (IDWP)

No topics

5.6. Vaccines Working Party (VWP)

Chair: Mair Powell

5.6.1. VWP 3-year workplan

The 3-year VWP workplan was endorsed by the VWP on 28 September 2022.

Action: For adoption

5.7. Haematology Working Party (HaemWP)

No topics

5.8. Scientific Advisory Groups (SAGs) and Ad-hoc Expert Groups (AHEG)

No topics

6. Patients, Healthcare Professionals and Consumers

6.1. Patients and Consumers Working Party (PCWP) Healthcare Professionals Working Party (HCPWP)

No topics

7. Harmonisation and consistency groups

7.1. International Council on Harmonisation (ICH)

7.1.1. ICH report to CHMP

Summary of the ICH bi-annual meeting in Incheon, South Korea (12-16 November 2023).

Action: For information

7.1.2. ICH E21 – Inclusion of pregnant women in CTs – appointment of experts

Following a call launched via CTCG, CHMP is requested to appoint an expert to the ICH working group drafting this new guidance document.

Action: For adoption

7.1.3. ICH Q13 – Continuous Manufacturing – Step 4 guideline

Following ICH adoption of this guideline, CHMP is requested to adopt the ICH document.

Action: For adoption

7.1.4. ICH M11 Clinical electronic Structured Harmonised Protocol (CeSHarP) – Step 2b – ongoing public consultation

This new harmonised Guideline on Clinical electronic Structured Harmonised Protocol (CeSHarP) is to introduce the clinical protocol template and the technical specification to ensure that protocols are prepared in a consistent fashion and provided in a harmonised data exchange format acceptable to the regulatory authorities. The public consultation is open until 26 February 2023. Members are invited to participate as volunteers, interested member can express their interest by **9 December 2022**.

Action: For information

7.2. Guideline Consistency Group (GCG)

No topics

7.3. Summary of product characteristics Advisory Group

No topics

8. Joint groups and collaboration with other Scientific committees

8.1. Joint CHMP/CVMP/CMDh/CMDv Working Group on Active Substance Master File Procedures (ASMF WG)

8.1.1. Update on Q&A guidance on Active Substance Master File (ASMF) (CMDh/CMDv/280/2012, Rev.12)

Update of Q&A guidance on Active Substance Master File (ASMF) (CMDh/CMDv/280/2012, Rev.12) with additional information. Questions 22, 23 and 25 have been updated and questions 26 and 27 have been added as new questions.

Action: For information

8.2. Collaboration with other Scientific committees

8.2.1. PRAC report to CHMP

Chair: Sabine Straus

Summary of recommendations and advice of PRAC meeting held on 28 November - 01 December 2022.

Action: For information

8.2.2. Revision of CHMP Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling (EMEA/CHMP/203927/2005)

Joint collaboration PRAC-CHMP for revision of the CHMP Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling. This activity is part of the CHMP Workplan 2023.

Action: For information

9. Regulatory/Organisational matters

9.1. Regulatory Issues/new legislation

9.2. CHMP organisation/templates

9.2.1. CHMP learnings

Collection, discussion and recording of CHMP learnings.

CHMP: Outi Mäki-Ikola

Action: For discussion

9.2.2. Practical working instructions for Multinational Assessment Teams (MNATs)

5-year update of guidance

CHMP: Outi Mäki-Ikola

Action: For discussion

10. Product development support

10.1. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi, Vice-Chair: Sylvie Louet

10.1.1. Appointment of CHMP peer review for SA

Action: For information

10.1.2. Agenda and Table of Decisions

- Agenda from 28 November - 01 December 2022 meeting held by Webex
- Draft Table of Decisions from 28 November - 01 December 2022 meeting held by Webex

Action: For information

10.2. Innovation Task Force

10.2.1. ITF meeting

Meeting date: 15 December 2022

Action: For adoption

10.2.2. ITF meeting

Meeting date: 21 December 2022

Action: For adoption

11. Product related topics

11.1. Preview CHMP Plenary

CHMP: Harald Enzmann

Action: For information

11.2. COVID-19 ongoing and upcoming procedures

List of currently ongoing and upcoming (imminently, i.e. expected within the next 2 months) applications for COVID-19 vaccines and therapeutics.

Action: For information

12. Any Other Business

12.1. Rapporteurships

Update

Action: For information

12.2. Diabetes Drafting Group - Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus - (CPMP/EWP/1080/00)

Update on the Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus (CPMP/EWP/1080/00) further to the comments received at the public consultation.

CHMP: Kristina Dunder

Expert: Peter Mol

Action: For adoption

12.3. Regulatory & Scientific conference on RNA based medicines

This conference on 2 February 2023 aims to facilitate the dialogue between industry/academia and regulators, to discuss scientific and regulatory opportunities and challenges to promote the development of RNA based innovative medicines.

Action: For information

12.4. Update on IRIS for core regulatory procedures

Update on how core regulatory procedures will be further implemented in IRIS and highlight open opportunities for NCA experts to contribute to ongoing work.

Action: For information

12.5. EMA labelling review process improvement

Streamlining proposals for improvement of EMA labelling review process.

Action: For information

12.6. Q&A "Is the monitoring of bioequivalence clinical trials mandatory?"

Q&A "Is the monitoring of bioequivalence clinical trials mandatory?" published on EMA corporate website – Q&A: Good clinical practice (GCP) | European Medicines Agency (europa.eu) please refer to B.16. A further clarification document: *Assessment of the adequacy of monitoring information in bioequivalence clinical trials* drafted.

CHMP: Jayne Crowe

Action: For information